Metachromatic Leukodystrophy (MLD) Clinical Trials

Metachromatic Leukodystrophy results from mutations in the ARSA gene encoding arylsulfatase A or in the PSAP gene encoding prosaposin, a required sulfatide activator protein. ARSA deficiency prevents breakdown of sulfatides, resulting in accumulation of these myelin components in oligodendrocytes, neurons, and peripheral tissues. Sulfatide accumulation triggers demyelination, neuronal dysfunction, and neuroinflammation.

The most common symptoms of Metachromatic Leukodystrophy include Late infantile form: weakness, clumsiness and loss of walking and talking skills, starting before about 30 months, Progressive loss of motor function and muscle tone, Loss of vision and hearing, Behavioral and cognitive decline, Seizures and spasticity, among others. Approximately 1 per 40,000 to 1 per 160,000 live births globally; variable by region. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Metachromatic Leukodystrophy from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Research in Metachromatic Leukodystrophy is advancing through gene therapy, enzyme replacement, and optimized hematopoietic stem cell transplantation approaches. The timing of intervention is crucial, with the best outcomes from early treatment before or very early in disease development, particularly in infants identified through newborn screening.

Yes. As of October 21, 2026, 1 FDA-approved medicine has a current label that names Metachromatic Leukodystrophy: Lenmeldy (atidarsagene autotemcel), first approved in 2024. Corticosteroids and immune globulins count once each.

Metachromatic Leukodystrophy is caused by variants in the ARSA and PSAP genes. Nearly all cases are ARSA; a few are PSAP (saposin B), and ARSA pseudodeficiency alleles can give low enzyme activity without disease.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child. Approximately 1 per 40,000 to 1 per 160,000 live births globally; variable by region. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Metachromatic Leukodystrophy looks at the ARSA and PSAP genes. Nearly all cases are ARSA; a few are PSAP (saposin B), and ARSA pseudodeficiency alleles can give low enzyme activity without disease.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Metachromatic Leukodystrophy clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Metachromatic Leukodystrophy clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.